Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibody-secreting plasma cells-Reference-Cited by-同舟云学术

Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibody-secreting plasma cells

Published:2012-04 Issue:4 Volume:105 Page:677-680
ISSN:1096-7192
Container-title:Molecular Genetics and Metabolism
language:en
Short-container-title:Molecular Genetics and Metabolism

Author:

Banugaria Suhrad G.,Patel Trusha T.,Mackey Joanne,Das Stuti,Amalfitano Andrea,Rosenberg Amy S.,Charrow Joel,Chen Y.-T.,Kishnani Priya S.

Publisher

Elsevier BV

Subject

Endocrinology,Genetics,Molecular Biology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference23 articles.

1. Glycogen storage disease type II: Acid a-glucosidase (acid maltase) deficiency;Hirschhorn,2009

2. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease;Kishnani;J. Pediatr.,2006

3. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature;van den Hout;Pediatrics,2003

4. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease;Nicolino;Genet. Med.,2009

5. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease;Kishnani;Pediatr. Res.,2009

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical pharmacology considerations for first‐in‐human clinical trials for enzyme replacement therapy;Journal of Inherited Metabolic Disease;2024-05-13

2. Advances in Immune Tolerance Induction in Enzyme Replacement Therapy;Pediatric Drugs;2024-04-25

3. A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics;Communications Medicine;2023-12-08

4. Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders;Advanced Drug Delivery Reviews;2023-06

5. Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease;Pediatric Nephrology;2022-07-21